Tokyo, Oct. 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059519) titled 'Special Drug Use Result Survey of IMAAVY in patients with generalized myasthenia gravis (limited to patients who do not sufficiently respond to steroids or immunosuppressants other than steroids)' on Oct. 29.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - generalized myasthenia gravis (limited to patients who do not sufficiently respond to steroids or immunosuppressants other than steroids)
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This survey is to be conducted in patients who receive IMAAVY 1200 mg...